ClinicalTrials.gg
CompletedNCT02312232NOCOFUpdated Feb 18, 2015

Pharmacokinetic Study in Healthy Males

A Phase 1 interventional study of levodopa, carbidopa, ODM-104 in Parkinson's Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-18.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Orion Corporation, Orion Pharma.

Enrollment
7th of 11
20 · median 27
Started
2014
the only one that year
Phase 1
4 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 1, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma is open now. The open studies under Parkinson Disease, anywhere →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) obtained.
  • Good general health ascertained by detailed medical history and physical examinations.
  • Finnish speaking males 18-65 years of age (inclusive).
  • Normal weight defined as a (BMI) > 19 and \< 32 kg/m2 (BMI = weight/height2).
  • Weight at least 60 kg.
  • Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems).
  • Participants with female partners of must adhere to a proper form of (hormonal contraception or intrauterine device on female partner, and an additional barrier method used at least by one of the partners) from the first study treatment administration until 3 months after the end-of-study visit.

Exclusion criteria

Exclusion Criteria:

  • Evidence of cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, , neurological or psychiatric disease within the previous 2 years.
  • Inherited or family history (parents, siblings) of clinically significant cardiac conduction disease.
  • Current/history of inflammatory bowel disease (IBDs): Colitis ulcerosa and Crohn's disease, celiac disease. Acute duodenal or gastric ulcer or gastritis, esophagitis, colon polyps or anal fissure.
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol for occasional pain is allowed.
  • Intake of any medication that could affect the outcome of the study.
  • Any clinically significant abnormal laboratory value or physical finding (including and vital signs) that in the opinion of the investigator may interfere with the interpretation of study results or constitute a health risk for the subject if he takes part in the study.
  • Known to the active substances or the of the drugs.
  • History of vasovagal collapses or vagal reactions with unexplained reason within 2 years or a tendency for vasovagal reactions during blood sampling.
  • History of sleep apnea.
  • Heart rate (HR) \< 40 bpm or > 90 bpm after 10 minutes in supine position at the screening visit and predose.
  • At the screening visit:

systolic blood pressure (BP) \< 90 mmHg or > 150 mmHg after 10 minutes in supine position diastolic BP \< 50 mmHg or > 90 mmHg after 10 minutes in supine position

  • Abnormal 24-hour Holter findings of clinical relevance according to cardiologist´s assessment at the screening visit.
  • History of anaphylactic/anaphylactoid reactions.
  • History of seizures excluding febrile seizures during the first 6 years of life.
  • Strong tendency to motion sickness.
  • Recent or current (suspected) drug abuse.
  • Recent or current alcohol abuse; regular drinking of more than 21 units per week (1 unit = 4 cl spirits or equivalent).
  • Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study (from the screening visit to the end-of-study visit).
  • Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from the use of caffeine containing beverages during the treatment periods until 24 hours after study treatment administration.
  • Blood donation or loss of significant amount of blood within 90 days prior to the first study treatment administration.
  • Administration of another drug within 90 days prior to the first study treatment administration.
  • Unsuitable veins for repeated venipuncture or for cannulation.
  • Predictable poor compliance or inability to communicate well with the study centre personnel.
  • Inability to participate in all treatment periods.
  • Participation in a clinical drug study during or within 3 months prior to the first study treatment administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Levodopa formulation A

    Levodopa formulation A together with ODM-104 100 mg and carbidopa

    Drug: levodopa, carbidopa, ODM-104

  • Experimental
    levodopa formulation B

    levodopa formulation B together with ODM-104 100 mg and carbidopa

    Drug: levodopa, carbidopa, ODM-104

  • Experimental
    levodopa formulation C

    levodopa formulation C together with ODM-104 100 mg and carbidopa

    Drug: levodopa, carbidopa, ODM-104

  • Active comparator
    Sinemet IR 100/25 mg

    Sinemet IR 100/25 mg together with ODM-104 100 mg

    Drug: levodopa, carbidopa, ODM-104

  • Active comparator
    Half Sinemet CR 100/25 mg

    Half Sinemet CR 100/25 mg together with ODM-104 100 mg

    Drug: levodopa, carbidopa, ODM-104

Interventions

  • Druglevodopa, carbidopa, ODM-104

    Also known as: Sinemet

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (Cmax) of levodopa

    Peak Plasma Concentration (Cmax)

    Time frame: 24 hours

Secondary outcomes

  1. Pharmacokinetics (Cmax) of carbidopa, 3-OMD and ODM-104

    Peak Plasma Concentration (Cmax)

    Time frame: 24 hours

07

Study locations

1 site
  • CRST
    Turku, 20520, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2014
First posted
Dec 9, 2014
Start
Nov 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Feb 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02312232
Responsible party
Sponsor
First posted
Dec 9, 2014
Start date
Nov 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Feb 18, 2015

Study contacts

Mika Scheinin, MD
principal investigator · CRST Turku

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion